A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
מצבים רפואיים
Chronic Lymphocytic Leukemia · Non-Hodgkin Lymphoma
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Contact: Principal Investigator (Alvaro Alencar)Florida Cancer Specialists, Sarasota, Florida, United States
Contact: Principal Investigator (Manish Patel)The Emory Clinic, Atlanta, Georgia, United States
Contact: Principal Investigator (Jonathon Cohen)Northwestern University, Chicago, Illinois, United States
Contact: Principal Investigator (Shuo Ma)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Jennifer Brown)Mayo Clinic- Minnesota, Rochester, Minnesota, United States
Contact: Principal Investigator (Yucai Wang)University Of Nebraska Medical Center, Omaha, Nebraska, United States
Contact: Principal Investigator (Matthew Lunning)Cayuga Cancer Center, Ithaca, New York, United States
Northwell Health, Lake Success, New York, United States
Contact: Principal Investigator (Steven Allen)Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, United States
Contact: Principal Investigator (Prioty Islam)Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Contact: Principal Investigator (Matthew McKinney)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Jennifer Woyach)University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (Sunita Nasta)Tennessee Oncology, Nashville, Tennessee, United States
Contact: Principal Investigator (Michael Byrne)University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Michael Wang)Swedish Cancer Institute, Seattle, Washington, United States
Contact: Principal Investigator (Swathi Namburi)Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact: Principal Investigator (Nirav Shah)Flinders Medical Centre, Adelaide, Australia
Contact: Principal Investigator (Hui-Peng Lee)Peter MacCallum Cancer Centre, Melbourne, Australia
Linear Clinical Research, Victoria, Australia
CHU de Nantes - Hotel Dieu, Nantes, France
Contact: Principal Investigator (Thomas Gastinne)IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi, Bologna, Italy
Ospedale San Raffaele, Milan, Italy
Contact: Principal Investigator (Paolo Ghia)Nagoya Medical Center, Aichi-Ken, Japan
National Cancer Center Hospital, Cho-ku, Japan
National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
Tokai University Hospital- Isehara Campus, Isehara, Japan
Tohoku University Hospital, Miyagi-Ken, Japan
Hokkaido University Hospital, Sapporo, Japan
Pratia MCM Krakow, Krakow, Poland
Contact: Principal Investigator (Wojciech Jurczak)Instytut Hermatologii I Transfuzjologii, Warsaw, Poland
Contact: Principal Investigator (Ewa Lech-Maranda)Seoul National University Hospital, Seoul, South Korea
Contact: Principal Investigator (Ja Min Byun)St James's University Hospital, Leeds, United Kingdom
Contact: Principal Investigator (Talha Munir)Churchill Hospital, Oxford, United Kingdom
Contact: Principal Investigator (Toby Eyre)Derriford Hospital, Plymouth, United Kingdom
Contact: Principal Investigator (David John Lewis)
מובילי המחקר
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company